The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2003-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1389557033488178PMID 12698949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.

  2002cited by this paper
• p53 regulation of DNA excision repair pathways.

  2002cited by this paper
• The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation

  2002cited by this paper
• Activation of the p53 tumor suppressor protein.

  2002cited by this paper
• The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

  2002cited by this paper
• Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.

  2002cited by this paper
• Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs

  2002cited by this paper
• A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants

  2002cited by this paper
• Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A.

  2002cited by this paper
• Therapeutic exploitation of the p53 pathway.

  2002cited by this paper
• ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus

  2002cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo

  2001cited by this paper
• p53 Latency

  2001cited by this paper
• Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

  2001cited by this paper
• Apoptosis of tumoral and nontumoral lymphoid cells is induced by both mdm2 and p53 antisense oligodeoxynucleotides.

  2001cited by this paper
• Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies.

  2001cited by this paper
• Defining the molecular basis of Arf and Hdm2 interactions.

  2001cited by this paper
• Rescuing the function of mutant p53

  2001cited by this paper
• Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

  2001cited by this paper
• Evidence for a Distinct Inhibitory Factor in the Regulation of p53 Functional Activity*

  2001cited by this paper
• P53 gene replacement for cancer--interactions with DNA damaging agents.

  2001cited by this paper
• Latent and active p53 are identical in conformation

  2001cited by this paper
• Identification of E2F-1/Cyclin A antagonists.

  2001cited by this paper
• Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells

  2001cited by this paper
• Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.

  2001cited by this paper
• Activation and activities of the p53 tumour suppressor protein

  2001cited by this paper
• Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein.

  2001cited by this paper
• Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.

  2001cited by this paper
• Conformational phenotype of p53 is linked to nuclear translocation

  2000cited by this paper
• A novel MDM2 anti‐sense oligonucleotide has anti‐tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer

  2000cited by this paper
• Apoptotic and Growth-Promoting Activity of E2F Modulated by MDM2

  2000cited by this paper
• Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

  2000cited by this paper
• In vitro evaluation of newly developed chalcone analogues in human cancer cells

  2000cited by this paper
• Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1.

  2000cited by this paper
• Letter to the Editor: Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53

  2000cited by this paper
• A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: affinity, stoichiometry, and thermodynamics.

  2000cited by this paper
• Strategies for manipulating the p53 pathway in the treatment of human cancer.

  2000cited by this paper
• A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

  2000cited by this paper
• p53 and human cancer: the first ten thousand mutations.

  2000cited by this paper
• Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex

  2000cited by this paper
• Small-molecule inhibitors of the cell cycle.

  2000cited by this paper
• Targeting gene expression to tumor cells with loss of wild-type p53 function

  2000cited by this paper
• Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

  2000cited by this paper
• An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo

  2000cited by this paper
• Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

  2000cited by this paper
• Activation of p53 in cervical carcinoma cells by small molecules.

  2000cited by this paper
• MDM2 oncogene as a novel target for human cancer therapy.

  2000cited by this paper
• MDM2--master regulator of the p53 tumor suppressor protein.

  2000cited by this paper
• Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines

  1999cited by this paper
• E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways.

  1999cited by this paper
• The cellular response to p53: the decision between life and death

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• Comparative study of the p53-mdm2 and p53-MDMX interfaces

  1999cited by this paper
• Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

  1999cited by this paper
• Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function.

  1999cited by this paper
• NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein

  1999cited by this paper
• New approaches to understanding p53 gene tumor mutation spectra.

  1999cited by this paper
• Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.

  1999cited by this paper
• Regulation of the p53 Tumor Suppressor Protein*

  1999cited by this paper
• A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

  1999cited by this paper
• Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression

  1999cited by this paper
• Transcription Factor E2F-1 Is Upregulated in Response to DNA Damage in a Manner Analogous to That of p53

  1999cited by this paper
• Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain

  1999cited by this paper
• p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53

  1999cited by this paper
• A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells.

  1999cited by this paper
• MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice

  1999cited by this paper
• p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin.

  1999cited by this paper
• Covalent and noncovalent modifiers of the p53 protein

  1999cited by this paper
• Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells*

  1999cited by this paper
• ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

  1998cited by this paper
• Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.

  1998cited by this paper
• Intercellular delivery of functional p53 by the herpesvirus protein VP22

  1998cited by this paper
• Regulation of p53 downstream genes.

  1998cited by this paper
• MDM2 expression during mouse embryogenesis and the requirement of p53.

  1998cited by this paper
• The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

  1998cited by this paper
• In vitro analysis of the dominant negative effect of p53 mutants.

  1998cited by this paper
• Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.

  1998cited by this paper
• Identification of an additional negative regulatory region for p53 sequence-specific DNA binding.

  1998cited by this paper
• The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2

  1998cited by this paper
• Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

  1998cited by this paper
• Functional interplay between p53 and E2F through co-activator p300

  1998cited by this paper
• Involvement of p53 and p21 in Cellular Defects and Tumorigenesis in Atm−/− Mice

  1998cited by this paper
• Reactivation of mutant p53: a new strategy for cancer therapy.

  1998cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• 14-3-3sigma is a p53-regulated inhibitor of G2/M progression.

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth.

  1997cited by this paper
• Molecular characterization of the hdm2-p53 interaction.

  1997cited by this paper
• CRM1 is an export receptor for leucine-rich nuclear export signals.

  1997cited by this paper
• Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo

  1997cited by this paper
• Transcription Abnormalities Potentiate Apoptosis of Normal Human Fibroblasts

  1997cited by this paper
• Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

  1997cited by this paper
• Recruitment of p300/CBP in p53-dependent signal pathways.

  1997cited by this paper
• Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis

  1997cited by this paper
• p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells.

  1997cited by this paper
• Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

  1997cited by this paper
• MDM2--arbiter of p53's destruction.

  1997cited by this paper
• Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation

  1997cited by this paper
• Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2

  1997cited by this paper

• Stochastic multi-scale modelling of tumour growth

  2017cites this paper
• Effective co-delivery of nutlin-3a and p53 genes via core-shell microparticles for disruption of MDM2-p53 interaction and reactivation of p53 in hepatocellular carcinoma.

  2017cites this paper
• Bacterial Carriers for Glioblastoma Therapy

  2016cites this paper
• Comparative validated molecular modeling of p53-HDM2 inhibitors as antiproliferative agents.

  2015cites this paper
• Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies.

  2013cites this paper
• oncogene Pathobiology of hemophilic synovitis I: overexpression of mdm2

  2013cites this paper
• Azaphilones: chemistry and biology.

  2013cites this paper
• Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy

  2012cites this paper
• QSAR Models for isoindolinone‐based p53–MDM2 Interaction Inhibitors Using Linear and Non‐linear Statistical Methods

  2012cites this paper
• Allosteric regulation of MDM2 protein

  2010cites this paper
• Genetic transformation of lignin degrading fungi facilitated by Agrobacterium tumefaciens

  2010cites this paper
• Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention

  2010cites this paper
• DISSECTING THE P53 PATHWAY BY MEANS OF SMALL MOLECULE- MEDIATED REACTIVATION AND COMPUTATIONAL BIOLOGY

  2009cites this paper
• Protopia: a protein-protein interaction tool

  2009cites this paper
• Beta-peptides with improved affinity for hDM2 and hDMX.

  2009cites this paper
• What induces pocket openings on protein surface patches involved in protein–protein interactions?

  2009cites this paper
• Epstein-Barr Virus Nuclear Antigen 3 C Augments Mdm 2-Mediated p 53 Ubiquitination and Degradation by Deubiquitinating Mdm 2

  2009cites this paper
• Unlocking the potential of RNA interference as a therapeutic tool

  2009cites this paper
• Computational design and analysis of binding pockets at protein-protein interaction interfaces

  2009cites this paper
• Epstein-Barr Virus Nuclear Antigen 3C Augments Mdm2-Mediated p53 Ubiquitination and Degradation by Deubiquitinating Mdm2

  2009cites this paper
• CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway.

  2008cites this paper
• SUMO-1 enhancing the p53-induced HepG2 cell apoptosis

  2008cites this paper
• Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

  2008cites this paper
• Inhibition of MDM2-p53 feedback loop by various small molecules for potential cancer chemotherapy

  2008cites this paper
• Knitting and untying the protein network: Modulation of protein ensembles as a therapeutic strategy

  2008cites this paper
• Recent Development in Novel Anticancer Therapies

  2007cites this paper
• Reactivation of mutant p53: molecular mechanisms and therapeutic potential

  2007cites this paper
• Transient pockets on protein surfaces involved in protein-protein interaction.

  2007cites this paper
• Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

  2006cites this paper
• Patented small molecule inhibitors of p53–MDM2 interaction

  2006influential citation
• Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53–HDM2 Protein–Protein Interaction

  2006cites this paper
• Bromoetherification-based strategy towards the spirocyclic chromophore of chlorofusin

  2006cites this paper
• Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.

  2005cites this paper
• SUMO-1 enhancing the p53-induced HepG2 cell apoptosis.

  2005cites this paper
• Cytotoxic effect of a non-peptidic small molecular inhibitor of the p53-HDM2 interaction on tumor cells.

  2005cites this paper
• Therapeutic Strategies Based on Pharmacological Modulation of p53 Pathway

  2005cites this paper
• Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

  2005cites this paper
• NMR structure of a complex between MDM2 and a small molecule inhibitor

  2004cites this paper
• Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level

  2004cites this paper
• Apoptotic responses common to cancer and inflammation

  2004cites this paper
• Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene.

  2004cites this paper
• Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?

  2004cites this paper
• Altered vegetable intake affects pivotal carcinogenesis pathways in colon mucosa from adenoma patients and controls.

  2004cites this paper
• Apoptosis: its pathophysiology and monitoring. The role of apoptosis in the radioiodine therapy of hyperthyroidism.

  2004cites this paper
• Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.

  2004cites this paper
• Cancer as a robust system: implications for anticancer therapy

  2004cites this paper
• Cancer and Inflammation

  2004cites this paper
• List Website Version Updated April 2018

  year unknowncites this paper